Alpha Cognition Inc (ACOG)

$5.31 -0.05 (-0.93%)
Market Cap 85.87M
Revenue (ttm) 0.00
Net Income (ttm) -13.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 21,400
Avg Vol 93,434
Day's Range N/A - N/A
Shares Out 16.02M
Stochastic %K 29%
Beta 2.50
Analysts Strong Buy
Price Target $50.00

Latest News on ACOG

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease

Feb 12, 2025, 8:30 AM EST - 24 days ago

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease

Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

Jan 30, 2025, 11:05 AM EST - 5 weeks ago

Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Jan 14, 2025, 8:30 AM EST - 7 weeks ago

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer's Disease, in China

Jan 8, 2025, 8:30 AM EST - 2 months ago

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer's Disease, in China

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer's Long-Term Care Market During Investor Update Call

Jan 6, 2025, 8:30 AM EST - 2 months ago

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer's Long-Term Care Market During Investor Update Call

Alpha Cognition Announces Partial Exercise of Over-allotment Option

Dec 16, 2024, 2:56 PM EST - 2 months ago

Alpha Cognition Announces Partial Exercise of Over-allotment Option

CSE Bulletin: Delist - Alpha Cognition Inc. (ACOG)

Dec 16, 2024, 11:51 AM EST - 2 months ago

CSE Bulletin: Delist - Alpha Cognition Inc. (ACOG)

Alpha Cognition Announces Voluntary Delisting from CSE

Dec 12, 2024, 6:41 PM EST - 3 months ago

Alpha Cognition Announces Voluntary Delisting from CSE

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Dec 11, 2024, 8:30 AM EST - 3 months ago

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

Nov 15, 2024, 5:00 PM EST - 4 months ago

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing

Nov 12, 2024, 9:22 AM EST - 4 months ago

Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing